In conclusion, we found 11 new drug candidates (tofacitinib, baricitinib, human immunoglobulin G, antithymocyte immunoglobulin, interferon alfa-n1, human interferon, ruxolitinib, upadacitinib, filgotinib, interferon alfa-2a, and interferon beta-1) for DM which supported both clinical and pre-clinical data. This evidence concerns the gene IFNB1 and dermatomyositis.